Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The CML Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning
Latest videos Conferences Topics Features Expert Editorial Board

Welcome to The Chronic Myeloid Leukemia (CML) Channel

VJHemOnc brings you the newest advances within the field of CML, with video interviews, podcasts, articles and more. The Chronic Myeloid Leukemia Channel provides coverage from key congresses on the latest developments in CML including therapy updates, managing cardiovascular toxicities and the role of transplantation in CML.

Conferences

ASH 2025
SOHO 2025
ESH CML/MPN 2025
ASH 2024
ASCO 2024
ASH 2023
2:07
Intronic DNA variants in EZH2 and GATA2 may predict TFR in CML
Shaun Patterson • 7 Dec 2025
2:19
CARDINAL: Phase I study of TERN-701, an allosteric BCR-ABL1 inhibitor, in previously treated CML
Elias Jabbour • 24 Nov 2025
2:36
Second-line therapy outcomes in CML after frontline second-generation TKI failure
Fadi Haddad • 7 Dec 2025
2:08
Predictive factors for successful treatment-free remission in CML
Fadi Haddad • 7 Dec 2025
View All Videos
1:48
Treatment-free remission in Ph+ ALL without alloSCT: ongoing research
Elisabetta Abruzzese • 4 Sep 2025
1:39
Aiming to further improve the outcomes of patients with CML
Jorge Cortes • 4 Sep 2025
2:09
Dynamically adjusting the dose and dosing schedule of TKIs in patients with CML
Jorge Cortes • 4 Sep 2025
3:00
Co-targeting in CML: practical considerations & the potential of the bone marrow microenvironment
Mhairi Copland • 4 Sep 2025
View All Videos
1:04
Prolonged follow-up of ASC4MORE: investigating the addition of asciminib to imatinib for CML
Giuseppe Saglio • 5 Mar 2025
3:49
Barriers to TKI discontinuation in patients with CML
Daniela Žáčková • 12 Mar 2025
2:12
The Phase II HALF study: investigating a gradual TKI treatment discontinuation strategy in CML
Daniela Žáčková • 12 Mar 2025
2:38
An overview of a session on treatment optimization in CML
Daniela Žáčková • 12 Mar 2025
View All Videos
1:45
Key CML updates from ASH 2024
Jorge Cortes • 7 Dec 2024
2:32
Findings from the ASC4FIRST study: asciminib compared with TKIs in CP-CML
Jorge Cortes • 7 Dec 2024
3:54
An analysis of the impact of ASXL1 mutations in patients with CP-CML treated in the SUSTRENIM trial
Simona Soverini • 7 Dec 2024
1:32
Novel agents in development for the treatment of CML
Simona Soverini • 7 Dec 2024
View All Videos
1:01
Advancements in CML: improving treatment-free remission and novel agents
Jorge Cortes • 1 Jun 2024
1:46
Asciminib versus other TKIs in the frontline treatment of CML: the ASC4FIRST study
Jorge Cortes • 1 Jun 2024
1:43
Dosing strategy of ponatinib in CP-CML: insights from the OPTIC trial
Jorge Cortes • 1 Jun 2024
View All Videos
2:02
Optimizing myeloablative conditioning with precision-engineered Orca-T in older patients
Caspian Oliai • 10 Dec 2023
3:21
A Phase I trial of Hu8F4, an anti-PR1/HLA-A2 monoclonal antibody, in R/R myeloid malignancies
Tapan Kadia • 14 Dec 2023
6:31
An overview of trials investigating asciminib in the treatment of Ph+ CML
Michael Mauro • 18 Dec 2023
4:02
Testing for BCR::ABL kinase mutations in CML and how they impact TKi resistance
Simona Soverini • 8 Dec 2023
View All Videos

Topics

Transplant
Immuno-Oncology
Trial Updates
Treatment
Diagnosis
Disease Biology
1:48
A pilot study of bortezomib plus PTCy as GvHD prophylaxis in patients undergoing haplo-SCT
Shatha Farhan • 17 Feb 2026
1:48
Treatment-free remission in Ph+ ALL without alloSCT: ongoing research
Elisabetta Abruzzese • 4 Sep 2025
3:00
Co-targeting in CML: practical considerations & the potential of the bone marrow microenvironment
Mhairi Copland • 4 Sep 2025
3:25
A multicenter analysis of the management and outcomes of patients diagnosed with CML in blast phase
Zhuoer Xie • 16 Dec 2024
View All Videos
1:19
Major breakthroughs in leukemia treatment: precision therapy and immunotherapy
Iskra Pusic • 11 Sep 2026
1:05
Biological barriers preventing patients from achieving durable remission in CML
Timothy Hughes • 11 Jun 2026
2:21
Exploring vaccination strategies in MPNs: the current research landscape
Morten Orebo Holmström • 27 Apr 2026
2:02
Optimizing myeloablative conditioning with precision-engineered Orca-T in older patients
Caspian Oliai • 10 Dec 2023
View All Videos
3:13
Phase I ENABLE trial of ELVN-001, a selective ATP-competitive inhibitor of BCR::ABL1, in R/R CML
Fadi Haddad • 10 Sep 2026
1:10
Ponatinib consolidation may improve second treatment-free remission in CML
Gonzalo Carreño Gómez-Tarragona • 12 Jun 2026
1:55
ENABLE study highlights the promise of ELVN-001 in chronic-phase CML
Dennis Kim • 13 Jun 2026
1:20
Week 144 analysis of the ASC4FIRST trial: asciminib in newly diagnosed chronic phase CML
Timothy Hughes • 11 Jun 2026
View All Videos
1:34
Can treatment-free remission become a reality in polycythemia vera?
Ruben Mesa • 2 Oct 2026
0:51
Beyond the label: optimal dosing strategies for CML in community practice
Fadi Haddad • 10 Sep 2026
2:17
Incorporating patient goals into frontline TKI selection in CML
Jorge Cortes • 10 Sep 2026
1:58
Optimizing frontline therapy selection to prevent resistance in CML
Jorge Cortes • 10 Sep 2026
View All Videos
2:22
Emerging technologies for molecular monitoring and mutation detection in CML
Simona Soverini • 10 Sep 2026
4:25
The Max Foundation: revolutionizing treatment access and accelerating health equity
Pat Garcia-Gonzalez • 15 May 2025
2:09
Essential diagnostic tests for CML: cytogenetics, FISH, and PCR
Simona Soverini • 5 Sep 2024
2:14
Guidance on mutational testing for diagnosing and monitoring CML
Simona Soverini • 5 Sep 2024
View All Videos
1:34
Can treatment-free remission become a reality in polycythemia vera?
Ruben Mesa • 2 Oct 2026
1:34
Managing patients with CML and additional genetic abnormalities
Jorge Cortes • 10 Sep 2026
2:22
Emerging technologies for molecular monitoring and mutation detection in CML
Simona Soverini • 10 Sep 2026
1:05
Biological barriers preventing patients from achieving durable remission in CML
Timothy Hughes • 11 Jun 2026
View All Videos

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals